Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Angiographic response to suprachoroidal triamcinolone acetonide (CLS-TA) in eyes with noninfectious uveitis
Author Affiliations & Notes
  • Ketaki Panse
    University of California Davis, Davis, California, United States
  • Abraham Hang
    University of California Davis, Davis, California, United States
  • Parisa Emami Naeini
    University of California Davis, Davis, California, United States
  • Kareem Moussa
    University of California Davis, Davis, California, United States
  • Footnotes
    Commercial Relationships   Ketaki Panse None; Abraham Hang None; Parisa Emami Naeini Bausch and Lomb, Code C (Consultant/Contractor), Eyepoint, Code C (Consultant/Contractor), Genentech, Code C (Consultant/Contractor), Knight Templar Eye Foundation, Code F (Financial Support); Kareem Moussa None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2629. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ketaki Panse, Abraham Hang, Parisa Emami Naeini, Kareem Moussa; Angiographic response to suprachoroidal triamcinolone acetonide (CLS-TA) in eyes with noninfectious uveitis. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2629.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Suprachoroidal triamcinolone acetonide (CLS-TA) is a safe and effective treatment for uveitic macular edema. Vascular leakage on fundus fluorescein angiography (FA), which is often present in intermediate, posterior, and panuveitis, is commonly used to assess disease activity in clinical practice. The impact of treatment with suprachoroidal CLS-TA on vascular leakage on FA, an important outcome measure in the treatment of uveitis, is currently unknown.

Methods : We conducted a retrospective chart review of patients with noninfectious uveitis who underwent suprachoroidal CLS-TA injection and had FA performed 6 weeks prior to the injection and 6 weeks after the injection. A previously published 40-point grading system for FA images was utilized to grade the FA images, and masked grading was performed independently by two graders. Scores between the two graders were averaged. Additionally, central subfield thickness (CST) on optical coherence tomography (OCT), best corrected visual acuity, and intraocular pressure (IOP) at the time of injection and at 6 week follow up were evaluated. Paired t-tests were performed, and p values less than 0.05 were considered significant.

Results : A total of 8 eyes from 8 patients were included. 4 out of the 8 (50%) patients were female. The median age was 73.5 years (range 25-82). All eyes had intermediate, posterior, or panuveitis.
The mean FA score before suprachoroidal CLS-TA injection was 12.3 (SD 4.7), and the mean score at 6-week follow-up was 11.0 (SD 2.1), with a mean difference of 1.3 (p-value = 0.852). Mean initial central subfield thickness on OCT was 408.4 (SD 44.5), and mean follow up CST was 337.7 (SD 30.5), with a mean difference of 70.7 (SD 25.3) (p-value = 0.0135). Mean initial visual acuity (LogMar) was 0.71 (SD 0.24) and mean visual acuity at 6 week follow up was 0.51 (SD 0.11), with a mean difference of 0.20 (p-value = 0.877). Mean initial IOP was 14.4 (SD 2.6), and mean IOP at 6 week follow up was 13.1 (SD 3.3) with a mean difference of 1.3 (p-value= 0.614).

Conclusions : While suprachoroidal CLS-TA is effective for the treatment of uveitic macular edema, it has minimal impact on vascular leakage on FA, a key outcome measure in the treatment of uveitis. Eyes with significant vascular leakage on FA may require supplemental or alternative treatment with systemic or local therapies to achieve disease control.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×